LOS ANGELES, April 30, 2020 /PRNewswire/ -- InvestorsHub NewsWire -- Cannabis Global, Inc. (OTCMKTS: MCTC) ("Cannabis Global" or the "Company"), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, is excited to announce a research breakthrough in the field of cannabinoid sciences resulting from the Company's 'Project Varin', which began earlier this year. The research program has yielded a new tetrahydrocannabivarin (THC-V) delivery system providing for sustained release of the cannabinoid over a predetermined period of time and two other delivery systems for immediate release.

Project Varin is a program to develop new delivery systems for varin cannabinoids. THC-V, which is one of the best known Varins, is becoming known within the cannabinoid sciences arena as the 'Skinny Cannabinoid' due to its purported appetite suppression qualities, and its possible use as a treatment against obesity-associated glucose intolerance. 

The technology being developed through this study will be implemented in coffee and tea products to be released in May 2020.  THC-V is similar in chemical structure to tetrahydrocannabinol (THC), but is non-psychoactive and not scheduled as a controlled substance. 

"While these developments add to our growing list of intellectual property, these are much more than technologies that will sit on a shelf," commented Arman Tabatabaei, CEO of Cannabis Global. "We have already integrated both the sustained and immediate release versions into beverage products that we expect to be available to consumers next month. We believe the field of minor and exotic cannabinoids will grow substantially this year with several product introductions. We are extremely excited at the prospect of being a first mover in this emerging market segment." 

The most significant of the developments produced a sustained release polymeric nanoparticle at ultra-high level loading, meaning the particles are mainly made of pure THC-V. These particles are designed to release the THC-V in a delayed manner. When used with immediate-release particles, they hold the promise to provide sustained dosing over many hours.

Other versions of the THC-V infusion technology are designed to provide immediate release via formulations that utilize none of the chemicals, such as emulsifiers and surfactants, that are often used in cannabinoid infusion delivery vehicles.  The nano-particle versions were developed based on the Company's pending patents filed late last year. The Company utilized both botanically derived and pharmaceutical-grade synthetic tetrahydrocannabinol to develop these infusion technologies.

About Cannabis Global, Inc.

Cannabis Global, Inc. (MCTC) is a Nevada registered, fully reporting and audited publicly-traded company. With the hemp and cannabis industries moving very quickly and with a growing number of market entrants, Cannabis Global plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The Company plans to actively pursue R&D programs and productization for exotic cannabinoid isolation, bioenhancement of cannabinoids and polymeric solid nanoparticles and nanofibers for addition into consumer products and for dermal application. The Company was reorganized during June of 2019 and announced its intent to enter the fast-growing cannabis sector. The Company is headed and managed by a group of highly experienced cannabis industry pioneers and entrepreneurs.

Forward-looking Statements

This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-k, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission